373 assets in Non-Hodgkin Lymphoma

Therapeutic assets addressing Non-Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Trimethoprim Non-Hodgkin Lymphoma	Monash University	P2/3	B (57)
cd22 car-transduced t cells Non-Hodgkin Lymphoma	Tongji Hospital	P1	B (56)
ab-205 Non-Hodgkin Lymphoma	Angiocrine Bioscience	P3	CCC (55)
Hpc, Cord Blood Non-Hodgkin Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Lisaftoclax Non-Hodgkin Lymphoma	Ascentage Pharma Group Inc.	P2	CCC (55)
Pertuzumab Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	CCC (55)
Polatuzumab Non-Hodgkin Lymphoma	Lazaros Lekakis	P2	CCC (55)
Trastuzumab Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	CCC (55)
Cobimetinib Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	CCC (54)
Moderna Bivalent Mrna Vaccine Non-Hodgkin Lymphoma	Monash University	P3	CCC (54)
Pfizer Bivalent Covid-19 Vaccine Non-Hodgkin Lymphoma	Monash University	P3	CCC (54)
Selinexor Non-Hodgkin Lymphoma	Mayo Clinic	P1/2	CCC (54)
Xembify Non-Hodgkin Lymphoma	Grifols Therapeutics LLC	P3	CCC (54)
Zilovertamab Non-Hodgkin Lymphoma	Oncternal Therapeutics, Inc	P3	CCC (54)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Non-Hodgkin Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Apg 115 Non-Hodgkin Lymphoma	Ascentage Pharma Group Inc.	P2	CCC (53)
Ari-0001 Non-Hodgkin Lymphoma	University Medical Center Groningen	P2	CCC (53)
Axi-Cel Non-Hodgkin Lymphoma	University Medical Center Groningen	P2	CCC (53)
cd45ra-depleted dli Non-Hodgkin Lymphoma	St. Jude Children's Research Hospital	P2	CCC (53)
Cucart19 Non-Hodgkin Lymphoma	Chi Kong Li	P2	CCC (53)
Emapalumab Non-Hodgkin Lymphoma	Marcela V. Maus, M.D.,Ph.D.	P2	CCC (53)
Ensartinib Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) Non-Hodgkin Lymphoma	Nektar Therapeutics	P2/3	CCC (53)
Lomustine Non-Hodgkin Lymphoma	Actuate Therapeutics Inc.	P2	CCC (53)
Mb-Cart19.1 Non-Hodgkin Lymphoma	King Hussein Cancer Center	P2	CCC (53)
Nemtabrutinib Non-Hodgkin Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (53)
NK-92 Non-Hodgkin Lymphoma	M.D. Anderson Cancer Center	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Paxalisib Non-Hodgkin Lymphoma	Lakshmi Nayak, MD	P2	CCC (53)
Selpercatinib Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Wztl-002 Car T-Cells Non-Hodgkin Lymphoma	Malaghan Institute of Medical Research	P2	CCC (53)
Letermovir Non-Hodgkin Lymphoma	City of Hope Medical Center	P2	CCC (52)
Mb-Cart20.1 Non-Hodgkin Lymphoma	Miltenyi Biomedicine GmbH	P1/2	CCC (52)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Non-Hodgkin Lymphoma	City of Hope Medical Center	P2	CCC (52)
Avadomide Non-Hodgkin Lymphoma	Bristol-Myers Squibb	P1/2	CCC (51)
Axitinib Non-Hodgkin Lymphoma	Canadian Cancer Trials Group	P2	CCC (51)
Azacytidine Non-Hodgkin Lymphoma	AbbVie	P1/2	CCC (51)
Crizotinib Non-Hodgkin Lymphoma	Canadian Cancer Trials Group	P2	CCC (51)
Degarelix Non-Hodgkin Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Fam-Trastuzumab Deruxtecan-Nxki Non-Hodgkin Lymphoma	American Society of Clinical Oncology	P2	CCC (51)
Iberdomide Non-Hodgkin Lymphoma	Hoffmann-La Roche	P1/2	CCC (51)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (51)
Linperlisib Non-Hodgkin Lymphoma	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (51)
L-Methionine Non-Hodgkin Lymphoma	St. Jude Children's Research Hospital	P2	CCC (51)
Mad Cpr 1 And 2 Non-Hodgkin Lymphoma	New York Medical College	P2	CCC (51)
Pomalidomide Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (51)
Retinol Non-Hodgkin Lymphoma	St. Petersburg State Pavlov Medical University	P2	CCC (51)

Showing 101 to 150 of 373 assets

PreviousPage 3 of 8Next